Labiana lifts adjusted EBITDA 10.2% in the first half on revenue of 41.26 million euros
Labiana Health, a Spanish pharmaceutical group listed on BME Growth, posted revenue of 41.26 million euros in the first half of 2026, up 5.2%, with adjusted EBITDA of 8.20 million (+10.2%) and adjusted EBIT of 6.19 million (+14.2%). Animal Health drove revenue with a 9.6% rise to 20.77 million. Net profit fell to 0.93 million due to 3.5 million in extraordinary financial expenses tied to the cancellation of the previous financing with Miralta/Blantyre.
In 35 seconds
- Revenue of 41.26 million euros, up 5.2% from the same period a year earlier.
- Adjusted EBITDA of 8.20 million (+10.2%) and EBITDA margin of 19.9%, versus 19.0% previously.
- Animal Health grew 9.6% to 20.77 million and accounted for 50.3% of consolidated revenue.
IASummary generated by artificial intelligence from a story by Animalshealth.es. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.